Two patients walk into a fracture clinic. One is a 70-year-old woman who tripped on a rug and broke her hip. The other is a six-year-old boy who broke his femur rolling over in his sleep. Both leave with casts. Both receive a bone density scan. And both, in many clinical settings, get the same diagnosis stamped on their chart: “fragile bones.”
But these two patients do not have the same disease. Not even close.
Osteogenesis imperfecta and osteoporosis are both bone fragility conditions. Both increase fracture risk. Both appear, superficially, as “weak bones” on imaging. But their causes are fundamentally different, their populations are entirely distinct, their treatments diverge sharply, and confusing the two – which happens with alarming regularity in general practice – leads directly to delayed diagnosis, inappropriate treatment, and preventable harm.
This article draws a precise, evidence-based line between these two conditions – explaining what each one is, how it develops, how it is diagnosed, how it is treated, and where the two conditions occasionally overlap in ways that complicate clinical management.
Why This Distinction Matters More Than You Think
The confusion between osteogenesis imperfecta (OI) and osteoporosis is not academic. It has real clinical consequences.
In published case reports, children with OI have been referred to child protective services for suspected non-accidental injury because clinicians failed to recognize a genetic bone disorder behind multiple unexplained fractures. Families have been separated. Investigations have been launched. These are not rare edge cases – they represent a documented failure pattern in emergency departments worldwide when OI is not considered in the differential diagnosis of childhood fractures.
On the other side, adults with undiagnosed mild OI are frequently managed for years as primary osteoporosis – receiving bisphosphonates for a disease that shares the same drug class but requires different dosing protocols, different monitoring parameters, and a fundamentally different clinical philosophy. Meanwhile, the genetic diagnosis – which carries implications for family planning and cascade screening – remains unmade.
Getting this distinction right is not simply good medicine. In some cases, it is the difference between protecting a family and destroying one.
The Foundational Difference: Collagen vs Bone Mass
Before examining symptoms, diagnosis, and treatment, it is worth anchoring the comparison in its molecular foundation – because the two conditions arise from entirely different biological mechanisms.
Osteogenesis Imperfecta: A Collagen Architecture Defect
OI is a genetic disorder of type I collagen – the primary structural protein of bone, tendon, ligament, skin, and sclera. In 85-90% of cases, the causative mutation lies in the COL1A1 or COL1A2 genes, either reducing the quantity of collagen produced or – more damagingly – altering its molecular structure in a way that disrupts the entire triple-helix scaffold upon which bone is built.
The result is not simply “less bone.” It is bone that is architecturally wrong from the moment of formation. The collagen fibers that should be organized in parallel, load-bearing arrays are instead thin, disorganized, and mechanically deficient. The bone mineral that is deposited into this faulty scaffold is often over-mineralized as a compensatory response – making OI bone hard and brittle rather than soft. This is why OI bone shatters rather than bends. It has compressive strength without the tensile flexibility that healthy collagen provides.
As explored in our detailed guide on OI types and clinical features, OI spans a spectrum from mildly affected adults with occasional fractures to perinatally lethal forms where the skeleton is incompatible with life.
Osteoporosis: A Bone Mass Depletion Disorder
Osteoporosis is defined by the World Health Organization as bone mineral density (BMD) more than 2.5 standard deviations below the mean peak bone mass of a young healthy adult, represented as a T-score of -2.5 or lower on dual-energy X-ray absorptiometry (DXA) scanning. It is fundamentally a disease of bone quantity, not bone quality.
In osteoporosis, the collagen is normal. The bone matrix architecture is essentially correct. What has changed is the balance between bone formation (driven by osteoblasts) and bone resorption (driven by osteoclasts). When resorption chronically exceeds formation – as occurs with estrogen deficiency after menopause, aging-related decline in osteoblast activity, prolonged corticosteroid use, or certain systemic diseases – bone mass progressively declines. The remaining bone is structurally sound at the microscopic level but insufficiently dense to withstand normal mechanical loading.
One in three women and one in five men over 50 will experience an osteoporotic fracture during their lifetime. It is a massive global public health burden – but it is an acquired, largely preventable and treatable condition, not a genetic one.
The table below captures the foundational distinction:
| Feature | Osteogenesis Imperfecta | Osteoporosis |
|---|---|---|
| Primary defect | Collagen structure or quantity | Bone mineral density |
| Cause | Genetic mutation | Acquired (aging, hormones, lifestyle) |
| Collagen quality | Defective | Normal |
| Bone architecture | Structurally abnormal | Structurally reduced, but normal type |
| Age of onset | Birth (congenital) | Middle age to elderly (acquired) |
| Bone appearance | Over-mineralized, brittle scaffold | Porous, reduced mass |
| Inheritance | Yes (dominant or recessive) | No (risk factors are heritable, disease is not) |
| Cure possible? | No – genetic | Yes/No – manageable, partially reversible |
Who Gets Each Condition?
Osteogenesis Imperfecta: A Disease of All Ages, Predominantly Pediatric
OI affects approximately 1 in 10,000 to 20,000 births with no predilection for sex, ethnicity, or geography. Because it is congenital, its manifestations begin in utero in severe forms – with fractures detectable on prenatal ultrasound – or in early infancy and childhood in milder forms. There is no age at which OI “develops.” It is present from conception.
Approximately 85-90% of OI cases are caused by autosomal dominant mutations in COL1A1 or COL1A2. This means a child of an affected parent has a 50% chance of inheriting the condition. However, a significant proportion of cases arise from de novo mutations – new genetic changes that were not inherited from either parent – meaning OI can appear in families with no prior history of bone fragility.
Adults with mild OI (Type I) may not receive a formal diagnosis until their thirties or forties, when the pattern of fractures, blue sclerae, hearing loss, and family history finally coheres into a recognizable clinical picture. This diagnostic delay is one of the most common and most consequential failures in OI care.
Osteoporosis: A Disease of Aging, Predominantly Postmenopausal
Osteoporosis is overwhelmingly a disease of the aging skeleton, driven by the hormonal and cellular changes of menopause in women and androgen decline in men. Estrogen plays a critical role in restraining osteoclast activity; when estrogen falls at menopause, osteoclasts become relatively unopposed, and net bone resorption accelerates. Women can lose up to 20% of their bone density in the first five to seven years after menopause.
Secondary osteoporosis – osteoporosis arising from another condition or medication rather than aging alone – can affect younger adults and even children. Common causes include prolonged corticosteroid use, hyperthyroidism, inflammatory bowel disease, anorexia nervosa, and calcium or vitamin D deficiency. In these populations, the distinction from OI becomes particularly important, as secondary osteoporosis in a young patient may superficially resemble mild OI.
Risk factors for osteoporosis include female sex, advanced age, postmenopausal status, low body weight, smoking, excessive alcohol, physical inactivity, family history of hip fracture, and dietary deficiencies in calcium and vitamin D. Unlike OI, osteoporosis risk can be quantified, tracked, and substantially modified by lifestyle intervention.
Clinical Presentation: How Each Condition Appears in Practice
How OI Presents
The clinical hallmarks of OI extend well beyond fractures. The condition is a systemic connective tissue disorder, and its manifestations reflect the ubiquity of type I collagen throughout the body.
Fracture pattern: In moderate to severe OI, fractures occur from minimal or no trauma – rolling over in bed, a sneeze, a gentle hug. In mild OI (Type I), fractures may occur with falls or minor impacts but heal normally and leave no deformity. Importantly, OI fractures occur in patterns atypical for osteoporosis: multiple fractures at different healing stages in a young child, long bone fractures in infants, and fractures in anatomical sites rarely involved in osteoporotic injury.
Blue sclerae: The thinned, collagen-deficient sclera in many OI types allows the underlying choroid vasculature to show through, producing a characteristic blue-grey tint. This sign is most pronounced in Type I and Type II OI and fades somewhat with age. Its presence in a fracture patient is a strong indicator of OI over osteoporosis.
Dentinogenesis imperfecta: Discolored, brittle, wearing teeth occur in a subset of OI types, reflecting collagen deficiency in the dentin layer. Osteoporosis does not affect teeth.
Short stature and skeletal deformity: Significant shortening or bowing of the long bones, scoliosis, and kyphosis are features of moderate to severe OI. Osteoporosis causes vertebral compression fractures leading to progressive height loss and kyphosis (“dowager’s hump”), but the mechanism and timeline differ entirely.
Hearing loss: Progressive sensorineural and conductive hearing loss affects a significant proportion of adult OI patients, particularly in Type I. Osteoporosis does not cause hearing loss.
Joint hypermobility and ligament laxity: Common in OI due to collagen deficiency in tendons and ligaments. Not a feature of osteoporosis. For those managing connective tissue resilience alongside bone fragility, this systemic collagen vulnerability is an important clinical consideration.
How Osteoporosis Presents
Osteoporosis is often called the “silent disease” precisely because it produces no symptoms until a fracture occurs. There are no external physical signs – no blue eyes, no dental abnormalities, no joint laxity – that signal its presence. The first clinical event is typically a fracture from a fall or, in advanced cases, from a sneeze or a minor twist.
Characteristic fracture sites: Osteoporotic fractures cluster in specific anatomical locations: the vertebral bodies (compression fractures producing back pain and height loss), the distal forearm (Colles’ fracture after a fall on an outstretched hand), the femoral neck (hip fracture, associated with the highest mortality of all osteoporotic injuries), and the proximal humerus. These sites reflect the trabecular bone predominance of osteoporotic loss. In contrast, OI fractures commonly involve diaphyseal long bones – the shafts of the femur, tibia, and humerus – a pattern less typical for acquired osteoporosis.
Progressive height loss: Vertebral compression fractures in osteoporosis accumulate silently, each reducing height by a few millimeters. Over years and decades, this produces the characteristic stooped posture and measured height loss of advanced osteoporosis. Yoga and posture-based exercise have documented roles in slowing this process through maintained spinal extensor strength and proprioceptive balance training.
Absence of systemic features: The isolated bone-specific nature of osteoporosis distinguishes it from OI. There are no sclerae findings, no dental abnormalities, no hearing changes, and no family history of childhood fractures. When these systemic features are present in an osteoporosis patient, the diagnosis should be revisited.
Diagnosis: Where the Pathways Diverge Most Clearly
Diagnosing Osteoporosis
The diagnostic workup for osteoporosis is largely standardized. DXA scanning of the lumbar spine and hip generates T-scores that place the patient on the WHO spectrum: normal (T-score above -1.0), osteopenia (-1.0 to -2.5), or osteoporosis (below -2.5). The FRAX tool – a validated algorithm incorporating clinical risk factors and BMD – estimates 10-year fracture probability and guides treatment decisions.
Laboratory investigations exclude secondary causes: thyroid function, parathyroid hormone, calcium, phosphate, 25-hydroxyvitamin D, full blood count, liver and renal function, and in selected cases, myeloma screen. When a secondary cause is identified, it is treated first – and in some cases, bone density recovers substantially without specific anti-osteoporosis pharmacotherapy. Find out more about osteoporosis management combining modern pharmacology and traditional herbal approaches in this clinical overview on SVK Herbal.
Diagnosing OI
OI diagnosis is more complex and often requires a multidisciplinary approach. In children presenting with multiple fractures, the clinical workup must systematically consider OI before concluding non-accidental injury. Key diagnostic steps include:
Clinical assessment: A thorough history covering fracture frequency, age at first fracture, family history of bone fragility, hearing loss, and dental abnormalities. Physical examination for blue sclerae, dentinogenesis imperfecta, short stature, limb deformity, and joint hypermobility.
Skeletal survey: Plain radiographs of the entire skeleton to identify fractures at different healing stages, wormian bones in the skull (small irregular ossicles within cranial sutures), cortical thinning, and deformity patterns inconsistent with osteoporosis.
DXA: Bone mineral density is typically low in OI, but the Z-scores must be interpreted with caution in children and adults with short stature because standard normative data may not correctly account for body size differences. Low BMD supports the diagnosis but cannot distinguish OI from osteoporosis or other metabolic bone diseases.
Molecular genetic testing: COL1A1 and COL1A2 sequencing confirms the diagnosis in 85-90% of OI cases. Expanded gene panels covering all currently identified OI-associated genes are increasingly available and should be considered when standard testing is negative in a clinically suspicious case. Genetic confirmation is essential for family counseling and cascade screening of at-risk relatives.
Bone biopsy: In ambiguous cases – particularly those with features of both OI and metabolic bone disease – iliac crest bone biopsy with tetracycline labeling and histomorphometry can identify the characteristic OI bone architecture changes and, in Type VI OI, the distinctive “fish scale” mineralization defect. It also directly distinguishes OI from osteomalacia and rickets, both of which can clinically mimic features of OI in young patients.
Treatment: Why the Overlap in Drugs Does Not Mean Overlap in Disease
Both OI and osteoporosis are treated with bisphosphonates. This pharmacological overlap is one of the primary reasons the two conditions are clinically conflated. But the similarities largely end there.
Treating Osteoporosis
Osteoporosis management centers on three pillars: lifestyle modification, calcium and vitamin D optimization, and pharmacological anti-resorptive or anabolic therapy.
Lifestyle: Weight-bearing exercise – particularly resistance training and impact loading – is the most potent non-pharmacological intervention for maintaining and building bone mass. As explored in the Naturem article on yoga and bone density, even isometric exercise has been shown to improve bone mineral density and reduce fracture risk in postmenopausal women. Fall prevention through balance training, environmental modification, and appropriate footwear is equally important.
Calcium and vitamin D: These are prerequisites for all osteoporosis pharmacotherapy. Calcium intake of 1,000-1,200 mg/day and vitamin D levels above 50 nmol/L are recommended as baseline adjuncts to all pharmacological regimens.
Pharmacotherapy: First-line agents are bisphosphonates (alendronate, risedronate, zoledronic acid), which inhibit osteoclast-mediated bone resorption and reduce fracture risk by 30-50% in postmenopausal women. Denosumab (a RANK-L inhibitor), romosozumab (anti-sclerostin), and teriparatide (parathyroid hormone analog) are second-line or specialist agents. Hormone replacement therapy remains an option for recently menopausal women with multiple risk factors.
Traditional and integrative support: In Vietnamese traditional medicine and Traditional Chinese Medicine, osteoporosis has been managed for centuries through herbs that tonify Kidney Essence and support bone metabolism. Drynaria Fortunei (Cốt Toái Bổ), used in the Naturem Joints+ formula, stimulates osteoblast activity and promotes calcium retention – functions with direct relevance to osteoporosis management. Hydroxytyrosol from olive oil has demonstrated anti-osteoporotic effects including enhanced osteoblast activity and inhibited osteoclast differentiation in preclinical models.
Treating OI
OI treatment is more complex, more individualized, and increasingly specialized with each passing year.
Bisphosphonates in OI: Intravenous pamidronate or zoledronic acid is the primary pharmacological intervention for OI, working through the same mechanism as in osteoporosis – reducing osteoclast activity and increasing bone mineral density. Response is generally most robust in quantitative collagen deficiency types (Type I) and more variable in types with severe structural defects. Unlike osteoporosis, where bisphosphonates straightforwardly reduce fracture risk across all treated patients, OI responses are more heterogeneous and require specialist monitoring.
Orthopedic surgery: Intramedullary rodding – surgically placing flexible or telescoping metal rods through the long bones – is a cornerstone of OI management for Types III and IV. This intervention prevents progressive deformity, stabilizes repeated fracture sites, and maintains ambulatory function. It has no analogue in osteoporosis management. Telescoping rod systems that elongate as the growing bone lengthens have dramatically improved outcomes for pediatric OI over the past two decades.
Emerging therapies: OI stands on the frontier of biological medicine in ways osteoporosis does not. Anti-sclerostin antibodies (romosozumab, also used in osteoporosis) show early promise specifically in OI by promoting bone formation. TGF-beta pathway inhibitors target a signaling dysregulation specific to OI bone remodeling. Mesenchymal stem cell transplantation – introducing cells capable of producing normal type I collagen – is in clinical trial for severe pediatric OI. Gene silencing therapies targeting the mutant collagen allele represent the most ambitious frontier. None of these approaches apply to osteoporosis, where the collagen gene is structurally normal.
Rehabilitation and physiotherapy: Both conditions benefit from physiotherapy, but the goals and constraints differ. Osteoporosis physiotherapy prioritizes impact loading, resistance training, and fall prevention. OI physiotherapy must achieve bone loading stimulus while accounting for real and individual-specific fracture risk – making aquatic therapy and isometric exercise particularly valued. Low-impact skeletal loading strategies appropriate for OI and osteoporosis alike include non-contact resistance exercise and hydrotherapy.
Collagen and nutritional support: OI patients cannot produce normal collagen regardless of nutritional status, but optimizing the collagen biosynthetic environment remains clinically rational. Adequate vitamin C is essential for the hydroxylation of proline and lysine residues that stabilize the collagen triple helix – deficiency would compound an already compromised system. Hydrolyzed collagen peptides from the Naturem Joints+ formula have been proposed as a supportive adjunct in OI, providing substrate and osteoblast signaling stimulus through the non-mutant collagen pathways. The same formula is used in osteoporosis management for its Drynaria Fortunei-mediated osteoblast support and its anti-inflammatory ingredients that reduce the inflammatory burden associated with chronic fracture and surgical recovery.
Where OI and Osteoporosis Overlap: The Clinically Confusing Cases
While OI and osteoporosis are distinct diseases, several clinical scenarios generate genuine diagnostic ambiguity.
Adult-Onset OI Presenting as “Premature Osteoporosis”
Mild OI (Type I) patients may present in their forties or fifties with low bone mineral density on DXA, a history of fractures greater than expected for age, and no known family history of OI. Without the alerting features of blue sclerae, dentinogenesis imperfecta, or childhood fractures, these patients are frequently diagnosed with primary or premature osteoporosis. Molecular genetic testing is the definitive differentiator, and it should be considered in any patient with osteoporotic DXA findings presenting below age 50 without a clear secondary cause.
OI Patients Developing Secondary Osteoporosis
Adults with OI – particularly those with moderate to severe forms who have spent significant time immobilized, on corticosteroids, or with limited ambulation – can develop superimposed secondary osteoporosis on top of their pre-existing OI. This is a situation of dual pathology: the OI skeleton is architecturally defective AND additionally depleted of bone mass. Management requires simultaneous attention to both mechanisms.
Pregnancy and OI vs Gestational Osteoporosis
A rare but documented condition – transient osteoporosis of pregnancy – can cause vertebral fractures during the third trimester or postpartum period in women with no prior bone disease history. In women with pre-existing mild OI, this pregnancy-associated bone loss can trigger their first recognized fractures, delaying the OI diagnosis further.
The Pediatric Differential
Children presenting with low bone mineral density, multiple fractures, and no family history of OI represent the most challenging clinical scenario. The differential diagnosis includes OI (de novo mutation), idiopathic juvenile osteoporosis, secondary osteoporosis from systemic illness, rickets and osteomalacia, and – critically and urgently – non-accidental injury. Systematic evaluation including genetic testing is mandatory in this population, both for clinical accuracy and for the protection of the family.
Traditional Medicine Perspectives: Shared Roots, Different Applications
Both osteogenesis imperfecta and osteoporosis involve bones that fail to withstand the mechanical demands of daily life. Traditional medicine systems have addressed bone fragility for millennia – without the benefit of molecular genetics to distinguish these conditions, but with remarkable empirical insight into the foods, herbs, and lifestyle practices that support skeletal resilience.
In Traditional Chinese Medicine, both conditions fall under the concept of “Kidney Deficiency” affecting the bones – since the Kidney organ system in TCM governs bone marrow, bone formation, and the fundamental constitutional vitality that determines musculoskeletal strength. The treatments prescribed – Drynaria Fortunei (Gu Sui Bu), Eucommia bark, prepared Rehmannia, Morinda root – are tonics for Kidney Yang or Kidney Essence that stimulate what modern medicine would recognize as osteoblast activity, calcium absorption, and bone remodeling balance.
The clinical specificity that distinguishes OI from osteoporosis in Western medicine does not map directly onto TCM categories, but the herbal interventions recommended for Kidney-deficient bone fragility in both children and elderly patients – the two populations most affected by OI and osteoporosis respectively – have substantial biological plausibility and emerging laboratory support.
The SVK Herbal clinical guide on traditional osteoporosis treatment notes that collagen, not calcium, is the underappreciated therapeutic target in adult bone health – precisely the molecule that OI teaches us is foundational to all skeletal integrity. Traditional medicine reached this insight empirically through the use of bone-based remedies like the hydrolyzed crocodile bone collagen used in Naturem Joints+, long before molecular biology confirmed type I collagen as the linchpin of skeletal architecture.
Conclusion: Two Different Problems Demanding Two Different Approaches
Osteogenesis imperfecta and osteoporosis both result in bones that break. That is where the similarity ends.
OI is a genetic disease present from birth, driven by defective type I collagen that structurally compromises the entire skeletal scaffold. It affects children and adults equally, spans a severity spectrum from mild to lethal, carries systemic manifestations in teeth, ears, eyes, heart, and lungs, and requires specialist multidisciplinary management that extends far beyond what standard osteoporosis care provides.
Osteoporosis is an acquired disease of aging, driven by progressive bone mass depletion when resorption chronically outpaces formation. It is preventable, modifiable, and substantially treatable through lifestyle, nutrition, and pharmacotherapy. It is a disease of quantity rather than quality – of too little bone, not of wrong bone.
Confusing the two costs families enormously. It delays genetic diagnoses with lifelong implications. It misframes treatment targets. And in the most serious cases, it has separated families by misidentifying a genetic disease as deliberate harm.
The medicine is clear. The distinction is learnable. And for every patient with unexplained bone fragility – at any age – asking the right questions about collagen and genetics is not optional. It is the foundation of correct diagnosis and compassionate care.
This article is for educational purposes and does not constitute individual medical advice. Anyone experiencing unexplained fractures, low bone density at a young age, or a family history of bone fragility should seek evaluation by a physician with expertise in metabolic bone disease.
Frequently Asked Questions (FAQs)
Yes, and this is one of the most clinically significant diagnostic pitfalls associated with both conditions. DXA scanning measures bone mineral density – a parameter that is low in both OI and osteoporosis. The scan cannot distinguish the cause of low density. A young adult with mild OI may have a T-score in the osteoporotic range and receive a diagnosis of primary osteoporosis without ever having their collagen genes tested. Clinical context – age of onset, fracture pattern, presence of blue sclerae, family history, hearing loss, and dental abnormalities – must always supplement the DXA result before a diagnosis is made. (NIH, 2024)
Partially. Bisphosphonates – the mainstay of osteoporosis pharmacotherapy – are also the primary pharmacological intervention in OI, working through the same mechanism of osteoclast inhibition. They increase bone mineral density and reduce fracture frequency in OI, particularly in quantitative collagen deficiency types. However, the response is less consistent in OI than in osteoporosis, and bisphosphonates do not correct the underlying collagen defect. OI also requires orthopedic surgical management, rehabilitation strategies, and emerging biologic therapies that have no role in standard osteoporosis care. (NCBI, 2021)
For osteoporosis, yes – substantially. Weight-bearing exercise, adequate calcium and vitamin D, smoking cessation, alcohol reduction, and fall prevention can significantly reduce osteoporotic fracture risk, and early intervention can partially reverse bone loss. For OI, lifestyle cannot prevent or reverse the genetic collagen defect, but it can meaningfully reduce fracture frequency. Appropriate low-impact exercise, nutritional optimization, and avoidance of high-impact activities are all clinically beneficial. Neither condition is immune to the benefits of an anti-inflammatory diet rich in polyphenols, omega-3 fatty acids, and mineral-dense whole foods. (SVK Herbal, 2025)
Osteoporosis itself is not a genetic disorder, but genetic factors substantially influence peak bone mass and the rate of bone loss. Variants in genes controlling bone density, calcium metabolism, and estrogen signaling contribute to familial clustering of osteoporosis risk. However, these are polygenic risk factors – numerous common variants each contributing a small effect – not single-gene mutations of the type that cause OI. A family history of hip fracture is a recognized independent risk factor for osteoporosis, but it does not indicate a monogenic bone disorder like OI. (WHO, 2023)
They should ask specifically whether OI has been excluded before accepting a diagnosis of primary or premature osteoporosis. Key questions to raise: Has my collagen gene been tested? Do I have blue sclerae? Is there any family history of childhood fractures or unexplained fracture frequency? Do I have any history of hearing loss or dental abnormalities? Has a bone biopsy been considered? Low bone density in a young adult without a clear secondary cause – corticosteroid use, inflammatory bowel disease, eating disorder, vitamin D deficiency – warrants molecular genetic testing for OI before a diagnosis of primary osteoporosis is accepted. (NCBI, 2021)
References:
Marini, J. C., Forlino, A., Bächinger, H. P., Bishop, N. J., Byers, P. H., De Paepe, A., Fassier, F., Fratzl-Zelman, N., Kozloff, K. M., Krakow, D., Montpetit, K., & Semler, O. (2017). Osteogenesis imperfecta. Nature Reviews Disease Primers, 3, 17052. https://doi.org/10.1038/nrdp.2017.52
Deguchi, M., Tsuji, S., Katsura, D., Kasahara, K., Kimura, F., & Murakami, T. (2021). Current overview of osteogenesis imperfecta. Medicina, 57(5), 464. https://doi.org/10.3390/medicina57050464
Altalib, A., Althomali, A., Alshahrani, A., Alfrayyan, A., & Aljughaiman, M. S. (2021). Osteogenesis imperfecta and child abuse from a forensic point of view. Cureus, 13(1), e12790. https://doi.org/10.7759/cureus.12790
Ramzan, K., Alotaibi, M., Huma, R., & Afzal, S. (2021). Detection of a recurrent TMEM38B gene deletion associated with recessive osteogenesis imperfecta. Diagnostics, 11(3), 571. https://doi.org/10.15190/d.2021.3
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011). Osteoporosis: Now and the future. The Lancet, 377(9773), 1276-1287.
World Health Organization. (2023). Musculoskeletal conditions. WHO Fact Sheet.
National Institutes of Health, National Library of Medicine. (2024). Osteogenesis imperfecta. StatPearls.
Fishman, L. M. (2009). Yoga for osteoporosis: A pilot study. Topics in Geriatric Rehabilitation, 25(3), 244-250.